关键词：肥胖；健康；不利影响；疾病；维持瘦身
摘 要：Obesity is a medical condition in which surplus body fat gets accumulated to a degree and can have a detrimental effect on the health of the individual. People suffering from obesity weigh 20 percent or more than their ideal body weight. Intake of excessive calories combined with the lack of physical activity is the most common cause of obesity in children and teenagers. Obesity is linked to the increased risk of illness, disability, and death. Though anti-obesity drugs are available in the market, their efficacy is restricted to maintenance of weight-loss rather than cure.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

03.2.1 Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Rate of Incidence and Prevalence

07.1 US

07.2 Europe

08. Types of Obesity

08.1 Monogenic Obesity

08.2 Polygenic Obesity

09. Causes of Obesity

09.1 Unhealthy Eating Habits

09.2 Sedentary Lifestyle

09.3 Certain Drugs

09.4 Lack of Sleep

09.5 Pregnancy

09.6 Medical Problems

10. Classification of Obesity

11. Market Segmentation by Drug Class

11.1 Peripherally Acting Anti-obesity Drugs

11.2 Centrally Acting Anti-obesity Drugs

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

14.1 Pipeline Status in 2014

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2013

20.3 Other Prominent Vendors

21. Key Vendor Analysis

21.1 Arena Pharmaceuticals

21.1.1 Key Facts

21.1.2 Business Overview

21.1.3 Geographical Segmentation

21.1.4 Business Strategy

21.1.5 Recent Developments

21.1.6 SWOT Analysis

21.2 F. Hoffmann-La Roche

21.2.1 Key Facts

21.2.2 Business Overview

21.2.3 Business Segmentation

21.2.4 Business Segmentation by Revenue 2012 and 2013

21.2.5 Revenue by Geographical Segmentation

21.2.6 Business Strategy

21.2.7 Key Information

21.2.8 SWOT Analysis

21.3 GlaxoSmithKline

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Business Segmentation

21.3.4 Business Segmentation by Revenue 2012 and 2013

21.3.5 Revenue by Geographical Segmentation

21.3.6 Pipeline Products

21.3.7 Business Strategy

21.3.8 Key Information

21.3.9 SWOT Analysis

21.4 Orexigen Therapeutics

21.4.1 Key Facts

21.4.2 Business Overview

21.4.3 Business Strategy

21.4.4 Recent Developments

21.4.5 SWOT Analysis

21.5 Vivus

21.5.1 Key Facts

21.5.2 Business Overview

21.5.3 Business Segmentation by Revenue 2013

21.5.4 Business Segmentation by Revenue 2012 and 2013

21.5.5 Geographical Segmentation by Revenue 2013

21.5.6 Business Strategy

21.5.7 Recent Information

21.5.8 SWOT Analysis

22. Other Reports in this Series